Abstract
A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.
Publication types
-
Review
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Humans
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
-
Mutation
-
Parkinson Disease* / drug therapy
Substances
-
LRRK2 protein, human
-
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2